For a woman under 50, the standard mammogram is often a source of anxiety rather than clarity. Dense breast tissue can obscure tumors, leading to false negatives and delayed diagnoses. The Blue Box Biomedical Solutions is building a diagnostic that sidesteps that anatomical uncertainty entirely, analyzing not images but the metabolic signature of cancer in a urine sample. Founded in 2021, the Barcelona startup is using a $3.2 million seed round to push its AI-powered test into clinical validation, with a clear-eyed focus on the population most poorly served by today’s screening [Femtech Insider, 2024].
A diagnostic built on metabolic breath
The core technology is an ‘electronic nose’,a small hardware device that uses chemical sensors to detect volatile organic compounds (VOCs) in urine. Machine learning algorithms are then trained to recognize the specific VOC profile associated with breast cancer. The company’s self-reported data, drawn from studies involving over 450 women across seven hospital partners, suggests a sensitivity of around 88% [The Blue Box, retrieved 2024] [MIT Solve, 2024]. The strategic claim is that this performance notably outpaces mammography for women under 50 and those with dense breasts, where the startup says its test is 30% more sensitive [MWC Barcelona, retrieved 2026]. For founder and CEO Judit Giró Benet, a biomedical engineer who conceived the device as a student project, the premise is disarmingly simple. "If dogs can smell it, so can we," she has said, referencing canine studies that show an ability to detect cancer through scent [Mundoamerica, 2025].
The team and the James Dyson pedigree
Judit Giró Benet’s journey from university research to funded startup provides a narrative backbone. She developed the initial prototype while pursuing a master’s at the University of California, Irvine, and her invention won the International James Dyson Award in 2020 [TechCrunch, 2021] [Dyson, 2020]. That early validation helped attract a clinical and scientific team to de-risk the academic concept. Dr. Júlia Solana Balaguer now serves as Scientific & Clinical Lead, and the company has brought on additional PhD researchers in biomedical engineering to advance the technology [LinkedIn, retrieved 2024]. The leadership table below outlines the core team shaping the company’s path to clinic.
| Name | Role | Key Background |
|---|---|---|
| Judit Giró Benet | CEO & Founder | Biomedical engineer, 2020 International James Dyson Award winner, UC Irvine master’s graduate. |
| Dr. Júlia Solana Balaguer | Scientific & Clinical Lead | PhD, leading clinical research and study design. |
| Lidia Navarro Farré, PhD | Research & Development | PhD contributor focused on building the urine-based test. |
A pragmatic path to the clinic
The company’s commercial strategy reflects a pragmatic understanding of medical device regulation. Rather than immediately positioning its test as a primary screening tool,a claim that would require exhaustive, multi-year trials for regulatory approval,The Blue Box is initially targeting a ‘rule-out’ diagnostic aid. In this model, used alongside existing methods, a negative result from The Blue Box could provide high confidence that cancer is not present, potentially reducing unnecessary follow-up imaging and biopsies for patients. The company cites a negative predictive value of over 95% for this use case [MIT Solve, 2024]. The planned business model is a Diagnostics-as-a-Service subscription for private gynecology clinics, creating a pay-per-test revenue stream shared with practitioners [MIT Solve, 2024]. The roadmap aims for clinical trials in 2025 and a launch in clinics by 2026 [MWC Barcelona, retrieved 2026].
The validation hurdle
For all its elegant logic, The Blue Box’s journey is just approaching its most consequential phase. The sensitivity figures that form the basis of its value proposition are self-reported from early studies. Independent, peer-reviewed clinical validation is the essential next step, and the planned 2025 trials will be the true test of the technology’s real-world performance. Furthermore, while the focus on younger women and dense breast tissue is a smart wedge, it also defines a specific, if sizable, initial market. Broad adoption would require demonstrating utility across a wider demographic. The competitive landscape, while not densely populated with identical urine-based tests, is defined by the entrenched standard of care: mammography, MRI, and ultrasound. Convincing clinicians to integrate a novel metabolic test into their diagnostic workflow will require not just compelling data, but also smooth integration and clear clinical guidelines.
The company’s near-term risks can be summarized in three parallel challenges:
- Clinical proof. The critical 2025 trials must validate the 88% sensitivity claim in a controlled, independent setting to gain medical credibility.
- Regulatory strategy. Navigating the FDA or EMA for a novel diagnostic will require a clear classification path, whether as an adjunctive tool or a screening device.
- Market education. The concept of a urine test for breast cancer, while non-invasive, represents a paradigm shift for both patients and physicians that requires significant communication.
The patient population in focus
The ambition here is squarely focused on a defined disease state: early-stage breast cancer. The target patient population is women aged 20 to 49, and particularly those with radiographically dense breast tissue, for whom mammography is less reliable. This group accounts for about a third of breast cancer cases but often falls outside routine screening programs, leading to diagnoses at later, more dangerous stages [MIT Solve, 2024].
Today, the standard of care for a woman in this cohort who feels a lump or has a family history typically involves a diagnostic mammogram, often followed by an ultrasound. If findings are ambiguous, the next step is an MRI or a biopsy,procedures that are costly, invasive, and anxiety-inducing. The Blue Box is betting that a simple, pain-free urine test could sit earlier in that cascade, providing a rapid, low-risk data point to help triage patients and reduce the burden of unnecessary procedures. The next twelve months, as the seed funding fuels those pivotal clinical trials, will determine if the metabolic signature in a urine sample can become a credible signal in the noisy, high-stakes world of oncology diagnostics.
Sources
- [Femtech Insider, 2024] Medtech Startup The Blue Box Closes €3M Seed Round to Transform Breast Cancer Screening | https://femtechinsider.com/medtech-startup-the-blue-box-closes-e3m-seed-round-to-transform-breast-cancer-screening/
- [MIT Solve, 2024] The Blue Box | https://solve.mit.edu/challenges/2024-global-health-challenge/solutions/83137
- [The Blue Box, retrieved 2024] Hello - The Blue Box Biomedical Solutions, S.L. | https://thebluebox.ai/
- [MWC Barcelona, retrieved 2026] The Blue Box Biomedical Solutions SL | https://www.mwcbarcelona.com/exhibitors/32092-the-blue-box-biomedical-solutions-sl
- [Mundoamerica, 2025] Judit Giró Benet, the engineer who has created a box that detects breast cancer | https://www.mundoamerica.com/lifestyle/2025/06/26/685ced0ee9cf4acd128b45a2.html
- [TechCrunch, 2021] The Blue Box is betting on the future of at-home breast cancer tests | https://techcrunch.com/2021/09/22/the-blue-box-is-betting-on-the-future-of-at-home-breast-cancer-tests/
- [Dyson, 2020] Interview: The Blue Box inventor Judit Giró Benet | https://www.dyson.com/newsroom/overview/features/november-2020/interview-the-blue-box-jda-2020
- [LinkedIn, retrieved 2024] The Blue Box Biomedical Solutions | LinkedIn | https://www.linkedin.com/company/thebluebox-ai